Quick10K

⚲

OWC Pharmaceutical Research

Filings

10-Q	2019-09-30	Filed 2019-11-13
10-Q	2019-06-30	Filed 2019-08-13
S-1	2019-05-31	Public Filing
10-Q	2019-03-31	Filed 2019-05-15
10-K	2018-12-31	Filed 2019-04-01
10-Q	2018-09-30	Filed 2018-11-08
10-Q	2018-06-30	Filed 2018-08-16
S-1	2018-06-14	Public Filing
10-Q	2018-03-31	Filed 2018-05-15
10-K	2017-12-31	Filed 2018-04-16
10-Q	2017-09-30	Filed 2017-11-14
10-Q	2017-06-30	Filed 2017-08-21
10-Q	2017-03-31	Filed 2017-05-18
10-K	2016-12-31	Filed 2017-04-17
10-Q	2016-09-30	Filed 2016-11-14
10-Q	2016-06-30	Filed 2016-08-29
10-Q	2016-03-31	Filed 2016-05-16
10-K	2015-12-31	Filed 2016-04-14
10-Q	2015-09-30	Filed 2015-11-13
10-Q	2015-06-30	Filed 2015-08-17
10-Q	2015-03-31	Filed 2015-05-15
10-K	2014-12-31	Filed 2015-04-01
10-Q	2014-09-30	Filed 2014-11-14
10-Q	2014-06-30	Filed 2014-07-29
10-Q	2014-03-31	Filed 2014-05-08
10-K	2013-12-31	Filed 2014-03-21
10-Q	2013-09-30	Filed 2013-11-07
10-Q	2013-06-30	Filed 2013-08-12
10-Q	2013-03-31	Filed 2013-05-14
10-K	2012-12-31	Filed 2013-04-15

Reports

8-K	2020-06-25	Officers, Other Events
8-K	2020-06-21
8-K	2020-03-30
8-K	2020-03-19
8-K	2020-03-12
8-K	2020-03-09
8-K	2019-12-20
8-K	2019-12-12
8-K	2019-11-13
8-K	2019-11-13
8-K	2019-10-22
8-K	2019-10-07
8-K	2019-09-16
8-K	2019-08-29
8-K	2019-07-24
8-K	2019-05-23
8-K	2019-05-06
8-K	2019-04-15
8-K	2019-04-04
8-K	2019-03-13
8-K	2019-02-22
8-K	2019-02-05
8-K	2019-02-01
8-K	2019-01-29
8-K	2018-12-31
8-K	2018-11-30
8-K	2018-11-30
8-K	2018-10-22
8-K	2018-08-21
8-K	2018-08-01
8-K	2018-06-28
8-K	2018-06-13
8-K	2018-04-30
8-K	2018-03-08
8-K	2018-03-05
8-K	2018-02-19

OWC Pharmaceutical Research Financials

OWCP Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin


Comps ($'000 TTM)	Market Cap	Gross Margin	EV/EBITDA	Ret on Assets	Assets	Liabilities	Revenue	G Profit	Net Income	EBITDA	EV
OWC Pharmaceutical Research (OWCP)	0	0%	-0.2	362%	1,773	1,467	100	0	6,420	6,420	-1,465
Headhunter Group (HHR)
United States Short Oil Fund (DNO)	0	-0%	0.0		0	0	-600	0	-1,856	-1,856	-0
Immune Therapeutics (IMUN)	0		0.0	-29,381%	8	13,479	0	0	-2,476	-2,475	-6
Juniper Industrial (JIH)
PositiveID Corp (PSID)
Live Current Media (LIVC)	0		2.8	-26%	418	108	0	0	-110	-109	-306
Sun Pacific Holding (SNPW)	0	30%	-17.5	-20%	6,669	10,975	260	77	-1,301	-315	5,510
Digatrade Financial (DIGAF)	0			0%	527	778	0	0	0	0	0
Lingerie Fighting Championships (BOTY)	0	-49%	0.2	-8,950,200%			23	-11	90	-10	-2
New Century Resources (NCRE)	0		0.0		0	205	0	0	-18	-17	-0
Arete Industries (ARET)
Renewable Energy Acquisition (REAC)	0		0.0	2,353,600%			0	0	-24	-22	-0
Sundial Growers (SNDL)
Energy Transfer Operating (ETP)	0	27%	5.8	4%	95,247,000	59,636,000	40,493,000	10,886,000	3,786,000	8,016,000	46,523,000
Blue Line Protection Group (BLPG)	0	40%	0.0	-189%	1,661	5,917	3,017	1,201	-3,138	-2,534	-19
ABCO Energy (ABCE)	0	38%	0.1	-173%	411	1,359	1,627	622	-713	-502	-28
Guided Therapeutics (GTHP)	0	332%	0.1	1,462%	404	16,413	28	93	5,908	6,835	439
Endonovo Therapeutics (ENDV)	0	73%	-0.8	-301%	3,414	19,980	204	150	-10,268	-9,617	7,448
Dominovas Energy (DNRG)


Balance Sheet ($'000)	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31	2019-06-30	2019-09-30
Cash	4	17	8	2	9	847	1,389	1,469	1,166	799	532	357	266	162	90	472		1,380	1,113	971	692	4,649	4,219	3,464	2,800	1,840	1,465
Accounts Receivable
Inventory
PP&E							26	29	29	28	26	23			18	37	14	11	10	46	33	33	33	73	35	33	31
Assets	4	17	8	2	9	847	1,437	1,523	1,195	840	568	430	343	239	130	497	2,076	1,413	1,218	1,061	736	4,774	4,312	3,553	2,949	2,335	1,773
Accounts Payable							12	17	37	53	45				9	8	5	36	40	65	71	128	231	98	163	104	286
Long-Term Debt
Liabilities		74	102	128		49	81	60	40	56	47	108	315	351	237	396	448	176	208	270	234	6,424	6,768	10,767	10,251	1,750	1,467
Stockholders' Equity		-57	-94			798	1,356	1,463	1,154	785	521	323	28	-150	-107	101	1,627	1,237	1,010	791	502	-2,183	-3,791	-9,440	-10,242	-3,043	-4,008


Income Statement ($'000)	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31	2019-06-30	2019-09-30
Revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	50	0	0	0	0		100	0		100	0
Cost of Revenue
Gross Profit
R&D	0	0	0	0	0	0	0	160	99	77	97	-15	37	35	30	-244	34	216	94	-782	155	273	126		285	320	168
SG&A	59	149	14	9	472	-107	4,354	154	305	533	311	245	222	84	75	-2,387	1,401	1,558	1,106	-6,851	821	756	543		498	395	519
Tax	0	0	0		0	0	0		0	0	0				0
Net Income	-71	-170	-42	-35	-509		-4,354	-315	-405		-408	-233	-314	-80	-141	-1,658	-1,435	-445	-1,201	-1,477	-977	-2,990	-991		-1,000	7,707	-287


Cash Flow ($'000)	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31	2019-06-30	2019-09-30
Cash Operating	-19	-49	-14	-9	-17	-22	-289	-274	-387	1,138	-1,795	-173	-172	-100	-126	-131	-191	-395	-274	-326	-371	-949	-427		-665	-955	-372
Cash Investing								-6	-2	-2	0	1				0	-1	0	-2	-6	-10	-10	-2		0	-2	0
Cash Financing	15	63	5	4	23	860	859	353	90	0	24	10	71	0	50	525	1,768	-273	10	189	105	4,918	0		0	0	0